MedTrace Logo

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

NCT00118781 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2005-07-19

No results posted yet for this study

Summary

This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.

Conditions

Interventions

DRUG

iseganan hydrochloride

Sponsors & Collaborators

  • IntraBiotics Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Marin Kollef, MD · Barnes-Jewish Hospital, Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00118781 on ClinicalTrials.gov